Dan Hertz joined the Department of Clinical Pharmacy in the College of Pharmacy in April 2013. He received his PharmD from the Ernest Mario School of Pharmacy at Rutgers University and his PhD in pharmaceutical sciences from the University of North Carolina Eshelman School of Pharmacy.

Interested in developing tools for individualizing cancer treatment, his current work focuses on the optimal use of paclitaxel in breast cancer. The approaches being developed include identifying an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity, particularly as it relates to neuropathy. Hertz is also interested in understanding the influence of patient genetics on cancer treatment outcomes. He uses several approaches to discover and validate the effect of common variants on drug exposure or patient sensitivity to toxicity. Much of this work is conducted through his membership in oncology cooperative groups, which provide access to sufficiently large patient cohorts for definitive analyses. 

Research Interests

  • Developing tools for individualizing cancer treatments

  • Understanding the role of patient genetics in treatment outcomes

  • Translating genetic associations into clinical practice to improve patient care

Selected Publications

  • Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irivin Jr. WJ, In Vivo Assessment of the Metabolic Activity of CYP2D6 Diplotypes and Alleles. Br J Clin Pharmacol. 2015 Apr 24. doi: 10.1111/bcp.12665. [Epub ahead of print] PMID: 25907378 (In Press)

  • McWhinney-Glass S*, Winham SJ*, Hertz DL, Yen-Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, and McLeod HL, Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity, Clin Cancer Res 2013 Oct 15;19(20):5769-76 doi:10.1158/1078-0432.CCR-13.0774 PMID: 23963862,  PMCID: PMC3798385

  • Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013 Jun;24(6):1472-8. PMID: 23413280, PMCID: PMC3660078

  • Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012 Jul;134(1):401-10. PMID: 22527101, PMCID: PMC3727245

  • Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC. Pilot Study of Rosiglitazone as an in vivo Probe of Paclitaxel Exposure, Br J Clin Pharmacol. 2012 Jul;74(1):197-200. PMID: 22680343, PMCID: PMC3394145